Auris Medical's Acute Inner Ear Hearing Loss Candidate Fails Phase III Trial

Auris Medical acknowledged today that its acute inner ear (sensorineural) hearing loss candidate AM-111 has failed a Phase III trial, a setback that has prompted the company to terminate a second late-stage trial.AM-111 missed its primary endpoint in the Phase III HEALOS trial ( NCT02561091 ) of statistically significant improvement in hearing from baseline to day 28 compared to placebo. Patients treated with 0.8 mg/mL of AM-111 showed a mean hearing improvement of 36.6 dB compared with 33.4 dB